通过移动应用程序改进ALK安排的非小细胞肺癌癌症的管理：一项基于物理学的调查。

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-08-01 Epub Date: 2023-09-14 DOI:10.2217/pgs-2023-0111

Ronaldo Elkaddoum, John Zakhour, Mary Hajal, Maroun Aoun, Maria Njeim, Mirvat Mahrous, Humaid O Al-Shamsi, Zineb Ben Brahim, Sami A Khatib, Hampig Raphael Kourie

{"title":"通过移动应用程序改进ALK安排的非小细胞肺癌癌症的管理：一项基于物理学的调查。","authors":"Ronaldo Elkaddoum, John Zakhour, Mary Hajal, Maroun Aoun, Maria Njeim, Mirvat Mahrous, Humaid O Al-Shamsi, Zineb Ben Brahim, Sami A Khatib, Hampig Raphael Kourie","doi":"10.2217/pgs-2023-0111","DOIUrl":null,"url":null,"abstract":"Background: ALK rearrangements account for around 5% of non-small-cell lung cancers. Aim: This study surveys physicians on the potential efficacy of a mobile application in improving the management of ALK-rearranged non-small-cell lung cancer, through knowledge, treatment adherence and real-time adverse events reporting. Materials & methods: A total of 118 physicians from 11 countries in the Middle East participated. Results & conclusion: Results indicate 94% support for enhancing team communication via an application, and 93% believe real-time adverse events reporting improves the quality of care. Participants found an ALK-rearrangement patient-physicians forum valuable for communication improvement. Motivations for application use included treatment planning (73%), care enhancement (60%) and contributing to publications (40%).","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Improving the management of ALK-rearranged non-small-cell lung cancer through a mobile application: a physicians-based survey.\",\"authors\":\"Ronaldo Elkaddoum, John Zakhour, Mary Hajal, Maroun Aoun, Maria Njeim, Mirvat Mahrous, Humaid O Al-Shamsi, Zineb Ben Brahim, Sami A Khatib, Hampig Raphael Kourie\",\"doi\":\"10.2217/pgs-2023-0111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: ALK rearrangements account for around 5% of non-small-cell lung cancers. Aim: This study surveys physicians on the potential efficacy of a mobile application in improving the management of ALK-rearranged non-small-cell lung cancer, through knowledge, treatment adherence and real-time adverse events reporting. Materials & methods: A total of 118 physicians from 11 countries in the Middle East participated. Results & conclusion: Results indicate 94% support for enhancing team communication via an application, and 93% believe real-time adverse events reporting improves the quality of care. Participants found an ALK-rearrangement patient-physicians forum valuable for communication improvement. Motivations for application use included treatment planning (73%), care enhancement (60%) and contributing to publications (40%).\",\"PeriodicalId\":20018,\"journal\":{\"name\":\"Pharmacogenomics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacogenomics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pgs-2023-0111\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0111","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

背景：ALK重排约占非小细胞肺癌的5%。目的：本研究通过知识、治疗依从性和实时不良事件报告，调查医生移动应用程序在改善ALK安排的非小细胞肺癌癌症管理方面的潜在疗效。材料与方法：共有来自中东11个国家的118名医生参与。结果和结论：结果表明94%的人支持通过应用程序加强团队沟通，93%的人认为实时不良事件报告可以提高护理质量。参与者发现ALK重排患者-医生论坛对改善沟通很有价值。应用程序使用的动机包括治疗计划（73%）、护理强化（60%）和对出版物的贡献（40%）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Improving the management of ALK-rearranged non-small-cell lung cancer through a mobile application: a physicians-based survey.

Background: ALK rearrangements account for around 5% of non-small-cell lung cancers. Aim: This study surveys physicians on the potential efficacy of a mobile application in improving the management of ALK-rearranged non-small-cell lung cancer, through knowledge, treatment adherence and real-time adverse events reporting. Materials & methods: A total of 118 physicians from 11 countries in the Middle East participated. Results & conclusion: Results indicate 94% support for enhancing team communication via an application, and 93% believe real-time adverse events reporting improves the quality of care. Participants found an ALK-rearrangement patient-physicians forum valuable for communication improvement. Motivations for application use included treatment planning (73%), care enhancement (60%) and contributing to publications (40%).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.